NCT06647329尚未招募1 期
CAR-T Technology for the Treatment of Recurrent/Refractory Malignant Hematological and Lymphatic Tumors: Multi-Center Clinical Study on Safety and Efficacy
Mingzhi Zhang1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2024年12月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- objective response rate(ORR)
研究概览
简要总结
evaluate the safety and Esfficacy of CAR-T technology for the treatment of recurrent/refractory malignant hematological lymphomas
详细描述
Patients with recurrent/refractory malignant hematological lymphomas were treated with CAR-T technology
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 14 Years 至 75 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants must meet all of the following conditions to be included:
- •The participant has given informed consent and signed the consent form, and is willing and capable of complying with the scheduled visits, study treatment, laboratory examinations, and other trial procedures.
- •Clinically diagnosed as having relapsed/refractory malignant hematologic tumors:
- •2.1 Diagnosed as CD19+ and/or CD20+ and/or CD22+ B-cell tumors through pathological and histological examinations, and the participant meets the criteria for relapsed or refractory B-cell malignancies as follows:
- •B-cell tumors include the following three categories:
- •A. B-cell acute lymphoblastic leukemia (B-ALL); B. Indolent B-cell lymphomas (CLL, FL, MZL, LPL, HCL); C. Aggressive B-cell lymphomas (DLBCL, BL, MCL).
- •Refractory/relapsed B-cell leukemia (meeting one of the following four criteria): A. Relapse within 6 months after initial remission; B. Initial refractory after 2 cycles of standard chemotherapy without achieving complete remission; C. Relapse or refractory after first-line or multi-line salvage chemotherapy without achieving complete remission; D. Not suitable for hematopoietic stem cell transplantation, or have abandoned transplantation due to conditions, or relapse after transplantation.
- •Refractory/relapsed B-cell lymphoma (meeting one of the first four criteria plus the fifth): A. Tumor shrinkage of less than 50% or disease progression after 4 cycles of standard chemotherapy; B. Achieved CR after standard chemotherapy, but relapsed within 6 months; C. Relapsed 2 times or more after achieving CR; D. Not suitable for hematopoietic stem cell transplantation, or have abandoned transplantation due to conditions, or relapse after transplantation;
- •E. The participant must have received sufficient prior treatment, including at least:
- •Anti-CD20 monoclonal antibodies
- •Combination chemotherapy containing anthracyclines.
- •2.2 Refractory/relapsed multiple myeloma: Progressed after at least 3 lines of treatment (at least one proteasome inhibitor and one immunomodulator used).
- •2.3 Presence of measurable or evaluable lesions: A. For lymphoma patients, a single lesion ≥15 mm or two or more lesions ≥10 mm, or PET-positive lesions determined according to Lugano criteria; B. For leukemia and myeloma patients, bone marrow MRD must be persistently positive or positive relapse.
- •Age 14-75 years (inclusive), both male and female.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-
- •Treatment-related antigen test results must be positive:
- •A. For lymphoma: CD19/CD20/CD22 (immunohistochemical results positive within six months); B. For acute lymphoblastic leukemia: CD19/CD22 (tumor cells detected positive by flow cytometry in bone marrow at screening, or extramedullary lesions with positive immunohistochemistry results within six months); C.For multiple myeloma: BCMA (tumor cells detected positive by flow cytometry in bone marrow at screening, or extramedullary lesions with positive immunohistochemistry results within six months).
- •Expected survival time greater than 3 months from the date of signing the informed consent form.
- •HGB ≥ 70 g/L (transfusion allowed).
- •Liver and kidney function, and cardiopulmonary function must meet the following requirements: a) Creatinine ≤ 1.5 × ULN; b) Left ventricular ejection fraction ≥ 50%; c) Blood oxygen saturation > 90%; d) Total bilirubin ≤ 1.5 × ULN; ALT and AST ≤ 2.5 × ULN.
- •Participants with a plan for pregnancy must agree to use contraception before enrollment and for six months after the study begins; if the participant becomes pregnant or suspects pregnancy, they must immediately notify the investigator.
排除标准
- •Participants who meet any of the following conditions are not eligible for inclusion:
- •History of any of the following cardiovascular diseases within the past 6 months: New York Heart Association (NYHA) class III or IV heart failure, cardiovascular intervention (angioplasty or stenting), myocardial infarction, unstable angina, or other clinically significant heart diseases.
- •History of severe pulmonary dysfunction.
- •Concurrent advanced malignant tumors.
- •Concurrent systemic fungal, bacterial, viral, or other infections that cannot be effectively controlled.
- •Concurrent severe autoimmune diseases or congenital immunodeficiency.
- •Active hepatitis (positive HBV DNA or HCV RNA testing).
- •Human Immunodeficiency Virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), or syphilis infection.
- •History of severe allergic reactions to biologics (including antibiotics).
- •Less than 6 months since undergoing allogeneic hematopoietic stem cell transplantation.
- •Acute or chronic graft-versus-host disease (GvHD).
- •History of deep vein thrombosis (DVT) (cancer-related thrombosis) or pulmonary embolism (PE) within 3 months prior to signing the informed consent form.
- •Anticoagulation treatment for DVT or PE within 3 months prior to signing the informed consent form.
- •History or clinical significance of CNS diseases at screening, such as epilepsy, seizure disorders, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or mental disorders.
- •Pregnant or breastfeeding women. Women of childbearing potential must have a negative serum pregnancy test within 48 hours prior to the start of lymphocyte-depleting chemotherapy.
- •Use of any of the following medications or treatments within the specified time before leukapheresis:
- •A. Use of alemtuzumab within the past 6 months prior to leukapheresis; B. Use of anti-CD20 monoclonal antibodies within 7 days prior to leukapheresis; C. Use of Venetoclax within 4 days prior to leukapheresis; D. Use of lenalidomide within 3 days prior to leukapheresis; E. Use of Idelalisib within 2 days prior to leukapheresis; F. Use of therapeutic doses of corticosteroids (defined as prednisone or equivalent > 20 mg/day) within 7 days prior to leukapheresis or 72 hours prior to CAR-T administration. However, physiological replacement, topical, and inhaled steroids are permitted; G. Use of investigational drugs within 4 weeks prior to leukapheresis. However, if treatment was ineffective or the disease progressed during the trial and at least 3 half-lives have elapsed before leukapheresis, enrollment is allowed; H. Received donor lymphocyte infusion (DLI) within 6 weeks prior to CAR-T administration.
- •Any factors judged by the investigator that may affect compliance with the study protocol, including uncontrollable medical, psychological, familial, sociological, or geographical factors, or unwillingness or inability to comply with the required procedures of the study protocol.
研究组 & 干预措施
Treatment
Experimental
CAR-T therapy
干预措施: CAR-T Therapy (Biological)
结局指标
主要结局
objective response rate(ORR)
时间窗: 6 months
evaluate the efficacy of CAR-T cell infusion for the treatment of relapsed/refractory malignant hematological tumors
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological MalignanciesMultiple MyelomaLymphomaAcute Lymphoblastic LeukemiaNCT05618041Hebei Senlang Biotechnology Inc., Ltd.50
招募中
不适用
CAR-T Cells in the Treatment of Malignant Hematological TumorsLymphoma, B-CellLeukemia, B-cellLeukemia, T-CellMultiple MyelomaNCT05619861Hebei Senlang Biotechnology Inc., Ltd.20
进行中（未招募）
早期 1 期
Clinical Study on the Safety and Efficacy of CAR-T/CAR-NK Cells in the Treatment of Recurrent Refractory or Unresectable Solid TumorsSafety and Efficacy of Cellular Drugs, Objective Response Rate of Subjects, EtcNCT06572956The Second Hospital of Shandong University10
招募中
不适用
Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in ChildrenLymphomaLeukemiaNCT04610125Hebei Senlang Biotechnology Inc., Ltd.30
Unknown
1 期
A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple MyelomaMultiple MyelomaNCT03767751Chinese PLA General Hospital80